Journalist at odds with local officials gunned down in Durango state

first_img MexicoAmericas Help by sharing this information Follow the news on Mexico MexicoAmericas 2011-2020: A study of journalist murders in Latin America confirms the importance of strengthening protection policies Reporters Without Borders urges the authorities to shed light on all aspects of journalist Carlos Ortega Melo Samper’s fatal shooting outside his home in Santa Maria del Oro, a town in the northern state of Durango, on 3 May. Municipal officials were known to have been extremely irked by Ortega’s columns for the Tiempo de Durango newspaper.“It is tragically symbolic that Ortega was gunned down on 3 May, a day dedicated to press freedom throughout the world, in what is now the western hemisphere’s most dangerous country for journalists,” Reporters Without Borders said, voicing its support for Ortega’s family and colleagues.“We join the Tiempo de Durango’s management in calling for a proper investigation into this murder and we would also like to know why the Durango state judicial authorities paid no attention to the threats that Ortega had received.”The Tiempo de Durango’s management told Reporters Without Borders that Ortega was intercepted by four men travelling in two vehicles as he was about to enter his home on the afternoon of 3 May. They tried to kidnap him and, when he resisted, they shot him twice.Ortega, who was also a lawyer, had criticised the local authorities about the poor hygiene in the municipal abattoir in a column on 28 April. It led to a serious altercation the next day with Mayor Martín Silvestre Herrera and the municipal official in charge of federal programmes, Juan Manuel Calderón Guzmán. Ortega also accused Calderón of defrauding the Durango Union of Livestock Breeders.The murder motive has yet to be established but the Tiempo de Durango’s management has urged the authorities not to neglect the possibility that he was killed because of his articles. His car was set on fire while parked outside his home two months ago, but the local representative of the public prosecutor’s department, Salvador Flores Triana, refused to order an investigation. The Durango state prosecutor’s office has just transferred Flores, replacing him by Héctor Pérez Martinez, who is now in charge of investigating the Ortega murder.Ortega had worked for the Tiempo de Durango for the past year, writing an often caustic column. He had previously written for El Siglo de Durango, another regional daily, for five years. According to the tally kept by the National Commission for Human Rights (CNDH), he is the 48th journalist to be murdered in Mexico since 2000, and the third since the start of 2009. May 5, 2021 Find out more News Organisation April 28, 2021 Find out more RSF_en center_img NSO Group hasn’t kept its promises on human rights, RSF and other NGOs say Reporter murdered in northwestern Mexico’s Sonora state May 13, 2021 Find out more to go further News Reports May 5, 2009 – Updated on January 20, 2016 Journalist at odds with local officials gunned down in Durango state News Receive email alertslast_img read more

Read more on Journalist at odds with local officials gunned down in Durango state

Arcus Biosciences Announces New Employment Inducement Grants

first_img Twitter Arcus Biosciences Announces New Employment Inducement Grants Local NewsBusiness By Digital AIM Web Support – February 9, 2021 WhatsApp Facebook Twitter HAYWARD, Calif.–(BUSINESS WIRE)–Feb 9, 2021– Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 126,200 shares of the Company’s common stock at an exercise price per share of $41.39, which was the closing price on February 8, 2021. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08. About Arcus Biosciences Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A 2a /A 2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. In addition, domvanalimab is advancing into ARC-10, Arcus’s “two in one trial” to support the potential approvals of both zimberelimab and zimberelimab + domvanalimab and a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage III NSCLC setting. AB308, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus’s combination regimens and is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit Inducement PR Source: Arcus Biosciences View source version on CONTACT: Katherine Bock VP Investor Relations & Corporate Strategy (510) 694-6231 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY SOURCE: Arcus Biosciences, Inc. Copyright Business Wire 2021. PUB: 02/09/2021 04:10 PM/DISC: 02/09/2021 04:11 PM Previous articleBlue Jackets C Mikko Koivu retires during 16th NHL seasonNext articlePrimerica Reports Fourth Quarter 2020 Results Digital AIM Web Support TAGS  WhatsApp Facebook Pinterest Pinterestlast_img read more

Read more on Arcus Biosciences Announces New Employment Inducement Grants

Pulis: Saido can earn England call

first_img Berahino is a minor doubt for the Saints game – along with James Morrison – after taking a knock in the 0-0 draw at Sunderland. He has already won an England call-up this season, for November’s games against Slovenia and Scotland, but failed to play and after eight goals in his last 10 games Pulis reckons Berahino will earn his place in the next squad on merit. He said: “Roy Hodgson picks the England team and the England squad and if he thinks that it is right to play him, brilliant. If he doesn’t I won’t go against Roy’s view. “But we have been really pleased with his form. I’m more concerned about Saido scoring goals for West Bromwich Albion. “Last week at Sunderland wasn’t a great performance but you have to look at his running stats and what he did for the team off the ball. “He’s got that in his mind now that even if he is not in possession of the ball, we need him to be in certain areas at certain times. “That enables us to keep the team nice and compact and solid.” The Baggies have lost just once since Pulis took over almost two months ago and have kept six clean sheets in his nine games. The Baggies boss believes Berahino is more of a team player as they continue to scrap for Barclays Premier League survival. Albion host Southampton on Saturday with the 16-goal striker aiming to win a place in the England squad for next month’s Euro 2016 qualifier with Lithuania and a friendly in Italy. West Brom head coach Tony Pulis insists Saido Berahino will earn an England recall if he deserves one. Last week’s draw at the Stadium of Light kept them five points clear of the bottom three but Pulis insists Albion’s job is only half done. “It’s very important you focus on every game, it’s not about a points tally at the moment,” he said. “We have to get as many points as we can. “We have 12 games to go and there are eight or nine clubs fighting to stay in the Premier League. I hope to God we stay up but we’re still in a dogfight. “I won’t be saying anything until we have achieved what would be a great success for us.” Press Associationlast_img read more

Read more on Pulis: Saido can earn England call